https://it.marketscreener.com/quotazioni/azione/RELMADA-THERAPEUTICS-INC-73538250/attualita/Relmada-Therapeutics-presentera-nuovi-dati-preclinici-sul-suo-programma-di-psilocibina-all-AASLD-th-45040706/?utm_source=telegram&utm_medium=social&utm_campaign=share